Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens

Neurology. Neuroimmunology and Neuroinflammation
A Bar-OrFrancoise Menguy-Vacheron

Abstract

To evaluate immune responses to neoantigen and recall antigens in healthy subjects treated with teriflunomide. This was a randomized, double-blind, placebo-controlled study. Subjects received oral teriflunomide (70 mg once daily for 5 days followed by 14 mg once daily for 25 days) or placebo for 30 days. Antibody responses were evaluated following rabies vaccination (neoantigen) applied at days 5, 12, and 31 of the treatment period. Occurrence of delayed-type hypersensitivity (DTH) to Candida albicans, Trichophyton, and tuberculin (recall antigens) was assessed before and at the end of treatment to investigate cellular memory response. Safety and pharmacokinetics were evaluated. Forty-six randomized subjects were treated (teriflunomide, n = 23; placebo, n = 23) and completed the rabies vaccination. Geometric mean titers for rabies antibodies were lower with teriflunomide at days 31 and 38 than with placebo. However, all subjects achieved sufficient seroprotection following rabies vaccination (titers well above the 0.5 IU/mL threshold). Overall, the DTH response to recall antigens in the teriflunomide group did not notably differ from responses in the placebo group. Following vaccination, geometric mean titers for rabies antibod...Continue Reading

Citations

Feb 10, 2016·Multiple Sclerosis and Related Disorders·Giancarlo ComiThomas P Leist
Jan 19, 2016·Frontiers in Immunology·Rui LiUNKNOWN MSSRF Canadian B cells in MS Team
Jan 14, 2016·CNS Drugs·Andrew ChanManuel Comabella
Feb 29, 2016·Current Neurology and Neuroscience Reports·Eric M L WilliamsonJoseph R Berger
Oct 6, 2016·Medical Microbiology and Immunology·Alessandra BuaPaola Molicotti
Jun 8, 2019·Multiple Sclerosis : Clinical and Laboratory Research·Giancarlo ComiMark S Freedman
Mar 13, 2019·Neurology. Clinical Practice·Edward J FoxAaron Boster
Apr 7, 2020·Immunology·Tohid GharibiBehzad Baradaran
Sep 18, 2020·Multiple Sclerosis : Clinical and Laboratory Research·Agostino RivaLucia Moiola
Apr 11, 2019·Therapeutic Advances in Neurological Disorders·Luisa KlotzHeinz Wiendl
Jul 8, 2020·Practical Neurology·Saúl ReyesG Giovannoni
Jun 22, 2018·Nature Immunology·Rui LiAmit Bar-Or
Jun 5, 2020·Journal of Neurology·Amir Hadi MaghziRohit Bakshi
Oct 23, 2020·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Tobias ZrzavyThomas Berger
Aug 10, 2020·Multiple Sclerosis and Related Disorders·John Robert CiottiAnne Haney Cross
May 1, 2019·Revue neurologique·C LebrunUNKNOWN French Group for Recommendations in Multiple Sclerosis (France4MS), the Société francophone de la sclérose en plaques (SFSEP
Apr 19, 2021·The Medical Journal of Australia·Cassie NesbittAnneke Van Der Walt
Jun 5, 2019·Multiple Sclerosis and Related Disorders·Christine LebrunUNKNOWN French Group for Recommendations in Multiple Sclerosis (France4MS) and the Société Francophone de la Sclérose En Plaques (SF
Mar 13, 2021·Current Opinion in Neurology·Susana Otero-RomeroChristine Lebrun-Frénay
Jun 3, 2021·Advances in Therapy·Patricia K CoyleScott D Newsome
Jul 9, 2021·Frontiers in Immunology·Christina WoopenTjalf Ziemssen
Jul 20, 2021·Expert Review of Neurotherapeutics·Gianmarco AbbadessaSimona Bonavita
Sep 7, 2021·Neurodegenerative Disease Management·Aaron E Miller

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01403376

Software Mentioned

TERIVA

Related Concepts

Related Feeds

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.